INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $198,105,511 | -10.2% | 3,803,139 | +9.1% | 1.25% | -6.3% |
| Q2 2023 | $220,671,403 | -9.0% | 3,485,019 | -22.2% | 1.34% | -11.5% |
| Q1 2023 | $242,569,040 | -3.3% | 4,479,576 | -5.5% | 1.51% | -10.5% |
| Q4 2022 | $250,848,473 | +2.8% | 4,740,145 | -9.6% | 1.69% | -0.4% |
| Q3 2022 | $243,970,000 | -20.7% | 5,243,290 | -2.7% | 1.70% | -12.9% |
| Q2 2022 | $307,722,000 | -32.7% | 5,391,065 | -27.9% | 1.94% | -13.7% |
| Q1 2022 | $457,571,000 | +6.2% | 7,477,868 | -9.2% | 2.25% | +28.2% |
| Q4 2021 | $431,029,000 | +42.3% | 8,235,171 | +1.4% | 1.76% | +42.8% |
| Q3 2021 | $302,826,000 | +14.0% | 8,123,004 | +24.8% | 1.23% | +14.2% |
| Q2 2021 | $265,607,000 | +20.0% | 6,506,789 | -0.3% | 1.08% | +8.5% |
| Q1 2021 | $221,405,000 | +9.9% | 6,525,323 | +3.0% | 0.99% | +0.3% |
| Q4 2020 | $201,418,000 | +45.1% | 6,333,900 | +17.1% | 0.99% | +12.2% |
| Q3 2020 | $138,792,000 | +47.7% | 5,408,879 | +47.8% | 0.88% | +29.9% |
| Q2 2020 | $93,967,000 | +108.5% | 3,660,594 | +24.8% | 0.68% | +45.0% |
| Q1 2020 | $45,069,000 | -26.3% | 2,932,265 | +64.6% | 0.47% | -6.4% |
| Q4 2019 | $61,130,000 | +103.8% | 1,781,699 | -55.6% | 0.50% | +75.2% |
| Q3 2019 | $29,998,000 | -1.6% | 4,015,760 | +71.0% | 0.29% | -3.7% |
| Q2 2019 | $30,477,000 | +6.0% | 2,348,032 | -0.6% | 0.30% | -5.1% |
| Q1 2019 | $28,765,000 | +27.3% | 2,361,619 | +19.0% | 0.31% | +4.0% |
| Q4 2018 | $22,598,000 | -46.0% | 1,984,058 | +2.9% | 0.30% | -37.0% |
| Q3 2018 | $41,838,000 | +24.1% | 1,928,018 | +1.0% | 0.48% | +17.7% |
| Q2 2018 | $33,718,000 | -14.9% | 1,908,231 | +1.4% | 0.41% | -20.7% |
| Q1 2018 | $39,623,000 | +42.2% | 1,882,342 | -2.2% | 0.51% | +38.4% |
| Q4 2017 | $27,873,000 | -10.3% | 1,924,917 | -2.3% | 0.37% | -12.3% |
| Q3 2017 | $31,089,000 | +50.8% | 1,970,181 | +18.7% | 0.42% | +47.0% |
| Q2 2017 | $20,611,000 | +26.2% | 1,659,513 | +65.1% | 0.29% | +19.1% |
| Q1 2017 | $16,333,000 | +6.6% | 1,005,113 | -1.0% | 0.24% | +4.3% |
| Q4 2016 | $15,316,000 | +32.9% | 1,014,948 | +34.3% | 0.23% | +34.3% |
| Q3 2016 | $11,522,000 | -63.4% | 756,011 | -6.9% | 0.17% | -64.3% |
| Q2 2016 | $31,515,000 | +42.0% | 811,812 | +1.3% | 0.48% | +42.2% |
| Q1 2016 | $22,189,000 | -47.9% | 801,036 | +1.2% | 0.34% | -42.2% |
| Q4 2015 | $42,577,000 | -2.1% | 791,542 | -27.1% | 0.59% | +1.0% |
| Q3 2015 | $43,482,000 | +20.6% | 1,085,973 | -3.8% | 0.58% | +47.8% |
| Q2 2015 | $36,067,000 | +50.7% | 1,128,871 | +12.7% | 0.39% | +58.5% |
| Q1 2015 | $23,928,000 | – | 1,002,002 | – | 0.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |